Joseph Pitts actually said...

"I was concerned that CMS finalized its Part B payment policy for biosimilars last year combining all biosimilars into one average sales price calculation and payment code."

"The Chair thanks the gentlelady. That concludes the questions that we have here. We have follow-up questions. We will submit those to you in writing. We ask that you please respond promptly."

"In 2009, this committee passed the Biologics Price Competition and Innovation Act (BPCIA) by a vote of 47 to 11."

"I urge my colleagues to support both of these amendments and the underlying resolution."